

Nothing Degrading about Saving Lives: E3 Ligands Recruiting New Drugs

<https://marketpublishers.com/r/N1012602EA7EN.html>

Date: April 2019

Pages: 12

Price: US\$ 1,250.00 (Single User License)

ID: N1012602EA7EN

Abstracts

REPORT INCLUDES:

An overview of E3 ligases, which have been long regarded as “undruggable targets”. Despite these failures both scientifically and financially, humiliations did not fully disrupt intense research efforts which persisted, due to the enormous potential upside

Discussion of underexploited strategies, traditional approaches that can be optimized, and novel techniques beginning to emerge and pay dividends

Information on the results propelling this field toward better clinical outcomes and insight into the Targeted Protein Degradation (TPD) which is renewing optimism in what was at one stage a field drowning in garbage proteins. Activity in the clinic is now being closely watched by the industry

REPORT HIGHLIGHTS:

Posttranslational modifications hit prime time in the pharma industry. There probably isn't a medium sized biopharmaceutical that does not have an active program ongoing, and certainly all of the big pharma companies are running multiple programs, and collaborations, for what we might have previously termed “undruggable targets”. Many of these are for highly unmet needs in neurodegeneration.

The properties of the structure that forms between a target, a degrader and an E3 ligase, are under intense investigation. Minor changes affect how the drugs work - this

can explain how promiscuous target-binding payloads can achieve super selectivity when transformed into a degrader. These minor alterations can also render the molecule complex not only ineffective, but sometimes toxic.

However, clinical results are beginning to write a compellingly effective story – the long and winding history of research into the ubiquitin proteasome may well have more blockbusters in store for us. And cures in a once overlooked corner of the cell machinery architecture.

Contents

CHAPTER 1 NOTHING DEGRADING ABOUT SAVING LIVES: E3 LIGANDS RECRUITING NEW DRUGS

Significance of Ubiquitin Proteasome System Discovery
Drug Discovery Approaches to Target E3 Ligases
Modulation of Protein-Protein Interactions
Allosteric Molecules
Screening Platforms
Targeted Protein Degradation and PROTACs- The Most Popular Trend of UPS Drug Discovery
Arvinas and Other "Rock Stars" Of UPS Drug Development Sector
Big Pharma Collaborations on TPD Platform
Importance Of TPD/Protacs Technology in Markets with Unmet Needs
Analyst's Credential
Related BCC Research Reports

CHAPTER 2 APPENDIX: REFERENCES

List Of Tables

LIST OF TABLES

Table 1: Examples of Companies Using Targeted Protein Degradation Platform in Drug Discovery

List Of Figures

LIST OF FIGURES

Figure 1: Schematic Presentation of Ubiquitin-Proteasome System

Figure 2: Annual Sales for Proteasome Inhibitors

Figure 3: Schematic Presentation of PROTAC Platform

Figure 4: Effect of PROTAC On Tau Levels in Hippocampus

I would like to order

Product name: Nothing Degrading about Saving Lives: E3 Ligands Recruiting New Drugs

Product link: <https://marketpublishers.com/r/N1012602EA7EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N1012602EA7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970